Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bimagrumab - Eli Lilly and Company

Next Previous
X
Search
Drug Profile

Bimagrumab - Eli Lilly and Company

Alternative Names: BYM-338; LY-3985863

Latest Information Update: 25 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MorphoSys; Novartis
  • Developer Eli Lilly and Company; Novartis
  • Class Anti-inflammatories; Antihyperglycaemics; Monoclonal antibodies; Obesity therapies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Inclusion body myositis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Obesity
  • Discontinued Cachexia; Inclusion body myositis; Muscular atrophy; Type 2 diabetes mellitus

Most Recent Events

  • 22 Mar 2024 Discontinued - Phase-II for Cachexia in Netherlands, Romania, Lithuania, Switzerland, Switzerland, United Kingdom, USA (IV) (Eli Lilly and Company pipeline, March 2024)
  • 22 Mar 2024 Discontinued - Phase-II for Muscular atrophy (In the elderly) in Japan, Taiwan, Chile, Belgium, Austria, Switzerland, Argentina, South Korea, Russia, Denmark, Colombia, France, Spain, Czech Republic, Hungary, Australia, Germany, Germany, United Kingdom, Mexico, Turkey, USA (IV) (Eli Lilly and Company pipeline, March 2024)
  • 22 Mar 2024 Discontinued - Phase-II for Type 2 diabetes mellitus in United Kingdom, USA (IV) (Eli Lilly and Company pipeline, March 2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top